| SBUX |
Report |
Adjusted diluted EPS |
BEAT |
pred ~$0.660 vs. cons $0.652 |
MEDIUM |
| SBUX |
Report |
U.S. comparable sales |
BEAT |
pred ~6.20% vs. cons 5.77% |
MEDIUM |
| SBUX |
Report |
Revenue |
IN-LINE |
pred ~$9.250B vs. cons $9.175B |
MEDIUM |
| SBUX |
Guide |
FY2026 adjusted EPS |
BETTER |
guide ~$2.25-$2.45 vs. cons $2.397 |
MEDIUM |
| SBUX |
Guide |
FY2026 global/U.S. comps |
UNCHANGED |
guide ~5% or better vs. cons U.S. 5.28% |
LOW |
| SBUX |
Guide |
FY2026 consolidated operating margin |
UNCHANGED |
guide ~slight YoY growth vs. cons UNVERIFIED |
LOW |
| SBUX |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
LOW |
| SBUX |
Return |
5-day cumulative residual |
-2.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — unchanged FY guide leaves an implied Q4 margin/earnings issue |
LOW |